Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

PXMD

PaxMedica Inc

Last Close
Apr 18 • 04:00PM ET
0.7631
Dollar change
-0.0368
Percentage change
-4.60 		%
Held by: VXF Scroll to Statements
Index- P/E- EPS (ttm)-15.19 Insider Own9.12% Shs Outstand7.40M Perf Week85.29%
Market Cap5.70M Forward P/E- EPS next Y- Insider Trans-5.26% Shs Float6.78M Perf Month19.22%
Income-18.29M PEG- EPS next Q- Inst Own1.48% Short Float1.97% Perf Quarter29.56%
Sales0.00M P/S- EPS this Y- Inst Trans- Short Ratio0.06 Perf Half Y-81.41%
Book/sh0.46 P/B1.67 EPS next Y- ROA-463.93% Short Interest0.13M Perf Year-97.76%
Cash/sh0.63 P/C1.21 EPS next 5Y- ROE-1046.96% 52W Range0.37 - 38.93 Perf YTD0.81%
Dividend Est.- P/FCF- EPS past 5Y- ROI-540.31% 52W High-98.04% Beta-0.26
Dividend TTM- Quick Ratio3.16 Sales past 5Y0.00% Gross Margin- 52W Low105.13% ATR (14)0.14
Dividend Ex-Date- Current Ratio3.16 EPS Y/Y TTM28.34% Oper. Margin0.00% RSI (14)59.11 Volatility37.07% 17.54%
Employees7 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price3.00
Option/ShortNo / No LT Debt/Eq0.00 EPS Q/Q89.15% Payout- Rel Volume0.30 Prev Close0.80
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume2.38M Price0.76
SMA2034.68% SMA5031.24% SMA200-80.90% Trades Volume720,736 Change-4.60%
Apr-16-24 04:30PM
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
(GlobeNewswire) -10.81%
Apr-12-24 07:51AM
Why Is PaxMedica (PXMD) Stock Up 93% Today?
(InvestorPlace) +103.71%
Apr-11-24 04:30PM
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
(GlobeNewswire)
Mar-13-24 08:20AM
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
(GlobeNewswire) -13.03%
Jan-18-24 08:30AM
IBN Highlights PaxMedica's Video Release on Transformative ASD Study
(NewMediaWire)
08:30AM Loading…
Jan-17-24 08:30AM
PaxMedica on Promising Path to Address Unmet ASD Needs
(NewMediaWire)
Dec-22-23 02:00PM
PaxMedica Files 8-K Following Nasdaq Compliance Achievement
(NewMediaWire)
Dec-19-23 09:30AM
PaxMedica CEO Howard Weisman Sheds Light on Achievements for ASD Therapy Pipeline
(NewMediaWire)
Dec-12-23 09:00AM
PaxMedica Inc. Covered in H.C. Wainwright & Co. Research Report
(NewMediaWire) -6.05%
Dec-08-23 08:30AM
PaxMedica CEO Featured in Just-Released Fireside Chat Video
(NewMediaWire) -9.28%
Dec-07-23 09:00AM
PaxMedica Closes Public Offering of Approximately $7M, Continues Pursuing ASD Pipeline
(NewMediaWire)
Dec-06-23 08:00AM
PaxMedica Releases Fireside Chat Video with CEO Howard Weisman
(ACCESSWIRE)
Dec-01-23 01:30PM
PaxMedica Closes on Public Offering Reaching Estimated $7M
(NewMediaWire)
Nov-22-23 04:10PM
PaxMedica Announces Closing of $7.0 Million Public Offering
(ACCESSWIRE) +27.50%
10:27AM
Why Is PaxMedica (PXMD) Stock Up 57% Today?
(InvestorPlace)
08:30AM Loading…
08:30AM
PaxMedica Announces Pricing of $7M Public Offering
(NewMediaWire)
Nov-21-23 09:00AM
PaxMedica News of FDA Type-B Meeting Shared in Audio Broadcast
(NewMediaWire) -18.37%
Nov-20-23 03:15PM
Why Is PaxMedica (PXMD) Stock Down 40% Today?
(InvestorPlace) -44.00%
09:15AM
PaxMedica Announces Pricing of $7.0 Million Public Offering
(ACCESSWIRE)
Nov-17-23 03:00PM
PaxMedica Releases Q3 2023 Financial Report, Corporate Update
(NewMediaWire) -13.37%
08:00AM
PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data
(GlobeNewswire)
Nov-15-23 06:50PM
PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update
(ACCESSWIRE) +11.52%
08:30AM
PaxMedica Hoping to Boost Patient Independence with Potential ASD Treatment
(NewMediaWire)
Nov-10-23 09:00AM
PaxMedica CMO Featured in Latest Bell2Bell Podcast Release
(NewMediaWire) -19.67%
Nov-09-23 08:30AM
PaxMedica Phase 2 Study Results Published in Peer-Reviewed Journal
(NewMediaWire) -30.92%
08:00AM
PaxMedica's Chief Medical Officer Discusses FDA Meeting Highlights on The Bell2Bell Podcast
(GlobeNewswire)
Nov-07-23 11:15AM
Why Is PaxMedica (PXMD) Stock Up 95% Today?
(InvestorPlace) +47.54%
08:00AM
PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal
(ACCESSWIRE)
Nov-02-23 08:30AM
PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV)
(GlobeNewswire) -17.31%
Oct-31-23 08:00AM
PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101
(GlobeNewswire) +11.76%
11:30AM Loading…
Oct-30-23 11:30AM
PaxMedica Announces 1-for-17 Reverse Stock Split
(GlobeNewswire) -16.68%
Oct-26-23 02:42PM
Why Is PaxMedica (PXMD) Stock Up Today?
(InvestorPlace) +26.96%
01:51PM
PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication
(GlobeNewswire)
08:00AM
PaxMedica Holds Important FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data
(ACCESSWIRE)
Oct-18-23 10:10AM
The Bell2Bell Podcast featuring Howard Weisman, CEO and Buzz Woods of PaxMedica, Inc. (Nasdaq: PXMD)
(GlobeNewswire) +34.62%
Oct-10-23 08:00AM
PaxMedica Announces Gold Sponsorship of The BRAIN Foundation's Synchrony Symposia 2023
(ACCESSWIRE) +7.96%
Aug-30-23 08:00AM
PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment Conference
(GlobeNewswire) -8.83%
Aug-16-23 08:30AM
PaxMedica Appoints David Hough M.D. as Chief Medical Officer
(GlobeNewswire)
Aug-09-23 04:15PM
PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update
(GlobeNewswire)
Aug-08-23 09:00AM
PaxMedica to Join Fireside Chat with PCG Advisory Following Positive Top Line Results from PAX-HAT-301 Study
(ACCESSWIRE)
Jul-24-23 08:00AM
PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301
(GlobeNewswire) +7.10%
Jul-06-23 08:00AM
PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC
(GlobeNewswire)
Jun-22-23 08:30AM
PaxMedica Comments on Common Stock Volatility
(GlobeNewswire)
Jun-20-23 08:30AM
PaxMedica CEO Interviewed by The BRAIN Foundation
(GlobeNewswire) -14.42%
Jun-14-23 08:00AM
PaxMedica Submits Clinical Trial Request in Autism Spectrum Disorder
(GlobeNewswire) -9.60%
Jun-08-23 08:00AM
PaxMedica Enters Research Collaboration Agreement With PoloMar Health for Phase II Study in Autism Spectrum Disorder
(GlobeNewswire) +7.63%
Jun-01-23 08:00AM
PaxMedica Completes HAT-301 Registrational Trial for PAX-101
(GlobeNewswire)
May-15-23 04:13PM
PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023
(GlobeNewswire)
Apr-19-23 08:30AM
PaxMedica Announces NASDAQ Closing Bell Ringing to Celebrate Initial Public Offering and Autism Awareness Month
(GlobeNewswire) -10.00%
Mar-29-23 07:21PM
PaxMedica, Inc. Provides Business Update and Reports Fourth Quarter 2022 Financial Results
(GlobeNewswire) +7.98%
Mar-20-23 08:00AM
PaxMedica Holds Meeting of Scientific Advisory Board
(GlobeNewswire)
Feb-27-23 10:22AM
7 Stocks With the Highest Short Interest This Week
(InvestorPlace)
Feb-15-23 07:30AM
PaxMedica Releases 2022 Shareholder Letter
(GlobeNewswire) +8.64%
Feb-03-23 08:00AM
PaxMedica, Inc. Secures $3.2 Million Growth Capital From Lind Partners
(GlobeNewswire) +9.03%
Jan-20-23 01:31PM
PaxMedica to Present at the Jan 26th Virtual Investor Summit Microcap Event
(GlobeNewswire) +5.07%
Dec-14-22 08:00AM
PaxMedica, Inc. Launches Updated Corporate Website at PaxMedica.com
(GlobeNewswire) -8.73%
Nov-22-22 08:00AM
PaxMedica to Present at the Benchmark Companys Upcoming Discovery One-on-One Investor Conference
(GlobeNewswire) -7.80%
Nov-17-22 08:29PM
PaxMedica, Inc. Enters Into Committed Equity Investment Agreement for up to $20 Million With Lincoln Park Capital
(GlobeNewswire) -9.64%
Nov-15-22 08:00AM
PaxMedica, Inc. Provides Business Update and Reports Third Quarter 2022 Financial Results
(GlobeNewswire) +15.79%
Nov-08-22 08:00AM
PaxMedica Initiates Clinical Program to Advance PAX-101 Towards FDA Submission
(GlobeNewswire)
Oct-24-22 08:00AM
PaxMedica Appoints Stefan Schwabe MD, PhD as Chief Medical Officer
(GlobeNewswire) -15.35%
Oct-03-22 08:00AM
PaxMedica Appoints Specialty Pharma Industry Leader Charles J. Casamento to Its Board of Directors
(GlobeNewswire) -5.83%
Aug-26-22 09:50AM
Craft Capital Management Announces Pricing of Initial Public Offering for PaxMedica, Inc.
(ACCESSWIRE)
08:00AM
PaxMedica, Inc. Announces Pricing of Initial Public Offering
(GlobeNewswire)
Aug-24-22 03:27PM
Neurodevelopment Biotech PaxMedica To Debut On NASDAQ Tomorrow
(Benzinga)
PaxMedica, Inc. is a clinical stage biopharmaceutical company. It engages in the business of developing drug candidates for the treatment of autism spectrum disorder, Fragile X syndrome tremor-ataxia, and Human African Trypanosomiasis. The company was founded by Michael L. Derby on April 5, 2018 and is headquartered in Tarrytown, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rome ZacharyDirectorJan 29 '24Sale0.4881138915,148Jan 31 07:55 PM
Weisman Howard J.Chief Executive OfficerJan 29 '24Sale0.4737217537,675Jan 31 05:16 PM
LaRochelle KarenDirectorJan 29 '24Sale0.4878372,829Jan 31 05:19 PM
Coelho John FDirectorJan 29 '24Sale0.4827134,615Jan 31 05:18 PM
Rome ZacharyDirectorNov 27 '23Sale1.0335937015,959Nov 29 04:07 PM
Derby Michael10% OwnerNov 27 '23Sale1.0318519025,650Nov 29 04:08 PM
Weisman Howard J.Chairman and CEONov 27 '23Sale1.0316216638,047Nov 29 04:08 PM
LaRochelle KarenDirectorNov 27 '23Sale1.0335362,907Nov 29 04:07 PM
Coelho John FDirectorNov 27 '23Sale1.0212124,642Nov 29 04:09 PM
Rome ZacharyDirectorOct 27 '23Sale0.1816,3013,012277,390Oct 30 04:13 PM
Derby Michael10% OwnerOct 27 '23Sale0.199,1751,740439,171Oct 30 04:12 PM
Weisman Howard J.Chairman and CEOOct 27 '23Sale0.198,0491,524649,549Oct 30 04:11 PM
LaRochelle KarenDirectorOct 27 '23Sale0.191,67931749,994Oct 30 04:12 PM
Coelho John FDirectorOct 27 '23Sale0.1957010879,090Oct 30 04:12 PM
Weisman Howard J.Chairman and CEOAug 30 '23Sale0.4522,53510,053657,598Aug 30 04:09 PM
Rome ZacharyDirectorAug 30 '23Sale0.474,8012,235293,691Aug 30 04:09 PM
Weisman Howard J.Chairman and CEOAug 29 '23Sale0.489,5964,650680,133Aug 30 04:09 PM
Rome ZacharyDirectorAug 29 '23Sale0.488,7924,257298,492Aug 30 04:09 PM
Derby Michael10% OwnerAug 29 '23Sale0.486,5403,169448,346Aug 30 04:08 PM
LaRochelle KarenDirectorAug 29 '23Sale0.4845622151,673Aug 30 04:09 PM
Coelho John FDirectorAug 29 '23Sale0.49231179,660Aug 30 04:10 PM
Rome ZacharyDirectorAug 28 '23Sale0.4912,0005,862307,284Aug 30 04:09 PM
Weisman Howard J.Chairman and CEOAug 28 '23Sale0.4912,0005,858689,729Aug 30 04:09 PM
Derby Michael10% OwnerAug 28 '23Sale0.497,0003,452454,886Aug 30 04:08 PM
LaRochelle KarenDirectorAug 28 '23Sale0.502,0001,00252,129Aug 30 04:09 PM
Coelho John FDirectorAug 28 '23Sale0.5277440379,683Aug 30 04:10 PM
Rome ZacharyDirectorAug 22 '23Sale0.5430,00016,236319,284Aug 23 04:12 PM
Rome ZacharyDirectorAug 21 '23Sale0.5820,00011,626349,284Aug 23 04:12 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.